Immune Regulation has been funded by visionary investors who have enabled us to take our lead molecules, PIN201104 and IRL201805, through preclinical development and successful early clinical trials. Our aim is to deliver truly transformative treatments for immuno-inflammatory disorders.

For more information please contact Richard Nagle,
Chief Executive Officer
+44 (0)1438 906978
email richard.nagle@immuneregulation.com